Parliament Workbench
Data: Official Report to 19 Nov 2026

Official Report · Committee

Current Petitions

Low-dose Naltrexone (PE1296)

Tuesday 8 February 2011 Public Petitions Committee About 14:00 Petitions 17 contributions · 6 speakers

Speakers

Choose an MSP to read only their contributions

The record

17 contributions
Rhona Brankin Lab The Convener · Midlothian
link

PE1296, by Robert Thomson, on behalf of LDN Now is on national health service availability of low-dose naltrexone.

Anne McLaughlin SNP Glasgow
link

This is the petition that I mentioned earlier. I know that the committee has facilitated a meeting involving the petitioners, the chief pharmaceutical officer and the deputy chief medical officer, which, from the note we have received, seems to have been fairly positive. However, we asked the Scottish Government whether it could put the petitioners in touch with researchers who might be interested in LDN research, but all it seems to have said is that that should happen without giving any advice, guidance, support or contacts to go on. As the petitioners have pointed out, most of the people involved are quite sick and all that they are looking for is a change in the approach to such matters.As for the issue of applications for research projects on the use of LDN for bladder dysfunction and multiple sclerosis, the Government has said that, having submitted an initial application, Dr Gilhooly was asked to submit a full application but no such application has been received. However, he needed the support of a neurologist or academic and thought that that person had to be someone in his own region. As a result of the meeting that I just mentioned, however, he thinks that someone in Tayside will support his full application.Nevertheless, in their letter, the petitioners have—quite rightly—pointed out that“if patients and their doctors show sufficient interest in a treatment not generally offered and there is sufficient evidence in the clinical setting that the treatment is worthwhile”and if industry, which tends to be profit driven, is not making these treatments available, the Government must find a way of stepping in and making it happen. They say:“We propose that what is needed is a mechanism whereby GPs and interested patients and patient groups can nominate treatments where research is not being taken up by private industry.”They make the good point that if they are right—the anecdotal and clinical evidence is that they are right, but they will not know until research is done—this is one example of a process that would save the health service a lot of money. However, it is not necessarily in the interests of the companies that provide the medicines and, therefore, is not necessarily in the interests of the companies that do the research.14:45

At present there are barriers. This is the petition on which I was going to suggest that we invite a minister, so that we can ask whether another approach is possible and whether the Government is willing to facilitate that. I am sure that we all remember the evidence session that we had on the petition. It was compelling listening to medical professionals and to individuals who have benefited from the treatment, which is not available everywhere because it depends on the general practitioner because research has not been done. As I say, the argument is that the research has not been done because it is not profitable.I acknowledge that asking about such an approach is not specifically what the petitioners called for, but we should consider the issue. We are living in difficult times of financial cuts, so we should consider anything that we can do that would reduce the financial burden on the national health service in the long term.

Rhona Brankin Lab The Convener · Midlothian
link

I note that the Scottish Government’s health services research committee has received an outline application for a research project into the use of LDN, but no full application has yet been submitted. The Government has contacted the individual concerned to ask where matters stand. In a sense, the door is not closed to possible Government support for a research project on LDN. However, we need to know what stage the process is at. Time might be against us.

Anne McLaughlin SNP Glasgow
link

That is what I was referring to. The Government spoke to the doctor who sent in the outline application and assured him that he could use a partner from anywhere in Scotland, and he now thinks that he might have one. However, the point that the petitioners are making is about more than just LDN; it is about medical research as a whole, the motivation for carrying out such research and the barriers to it. One barrier was that the doctor had to get an academic partner. The petitioners are saying that if GPs, patients and patient groups believe that there is clinical evidence, there must be a way of enabling research to be carried out without having to depend on the big pharmaceutical companies, which might have no interest in doing such research.

Rhona Brankin Lab The Convener · Midlothian
link

I assume that that is where the Government’s health services research committee comes in, but it would be interesting to clarify that. I ask the clerk to clarify how wide the terms of the petition are.

Fergus Cochrane
link

The petition is specific to LDN, although I hear what Anne McLaughlin says. It talks about making LDN“readily available on the NHS”.However, there is probably a bit of scope to look at the research process. I do not think that Anne McLaughlin’s suggestion would take us outwith the scope of the petition, although to start looking at the whole research procedure would likely take us down a different route.

Cathie Craigie Lab Cumbernauld and Kilsyth
link

The new evidence that Anne McLaughlin has mentioned should allow us to continue the petition so that we get updated information. I accept Fergus Cochrane’s point about straying into a wider remit than the petition allows. However, new information has arisen so, before we close the petition, we should look at all aspects that are worthy of consideration.

Rhona Brankin Lab The Convener · Midlothian
link

I ask Anne McLaughlin to clarify her suggestion. Is it that we should ask the minister about the matter in person?

Anne McLaughlin SNP Glasgow
link

This is the petition that I was referring to earlier, when I said that I would like to invite a minister to appear before the committee to answer some questions on certain issues. I would like to know what would stop research being done. I do not think that this Government or the previous Executive would have any difficulty with the principle of enabling research regardless of whether it is profitable for pharmaceutical companies. I hope that someone lodges a new petition on the subject at some stage. It would be useful for us to get a bit more information on the barriers and why we are not enabling groups to get research carried out when pharmaceutical companies are not interested. Regardless of what I said earlier about our not having time to call a minister to appear before us in relation to PE1263, my ideal would be to ask the cabinet secretary to come to speak to us on this petition. However, I know that we are running short of time, so I would be happy for us to write to the Government to find out what its stance is on the issue. At that point, either the petitioners or another group of people—I might even do it myself, if I am not an MSP after the election—should lodge a new petition on the subject.It would be good to understand what the barriers are and why nothing is being done to enable the petitioners to do what they suggest.

Rhona Brankin Lab The Convener · Midlothian
link

It certainly raises huge issues, which other people have come up against in respect of drug therapies that they have found helpful.We will write to the minister. We could ask either the minister or the cabinet secretary to come to our meeting on 1 March to discuss the issue.

Anne McLaughlin SNP Glasgow
link

That would be ideal, but I am aware that we do not have a lot of time and that there are many other petitions to deal with.

Rhona Brankin Lab The Convener · Midlothian
link

It depends on the priority that the committee wants to give the issue.

Anne McLaughlin SNP Glasgow
link

I think that it would be helpful to talk to the cabinet secretary about the issue as it would enable us to include some useful evidence in our legacy paper. The petition has raised wider issues that will become more important in the coming years, as the financial cuts dig in.

Bill Butler Lab Glasgow Anniesland
link

Anne McLaughlin is right. We should try to fit in a brief oral evidence session that we can use to inform the deliberations of our successor committee.

Fergus Cochrane
link

Currently, seven petitions are scheduled to be discussed on 1 March. As I said, our intention was to include anything that comes out of today’s meeting in that meeting. You have an oral evidence-taking session with the commissioners on PE1351 and, possibly, two sessions with the Cabinet Secretary for Health and Wellbeing. It is entirely a decision for the committee if it wants to have three evidence sessions. In the past, you have allocated time slots in which each petition can be dealt with. The availability of ministers is stretched at the moment. Would you need to speak to a minister? Previously, you have invited officials to appear before the committee. Might it be useful to invite the chief scientific officer or the chief pharmaceutical officer—or both—to give evidence on the issue as an alternative, if the minister is not available? If you are interested in the process, they would also be helpful.

Nigel Don SNP North East Scotland
link

That is a sensible suggestion. Indeed, it might well be better to speak to them than to a minister, but I would not presume to know whether that is the case.

Rhona Brankin Lab The Convener · Midlothian
link

Do we agree to follow the suggested course of action?Members indicated agreement.

  1. 14:00 Current Petitions Petitions · 1
  2. 14:00 Current Petitions Petitions · 11
  3. 14:00 Current Petitions Petitions · 5
  4. 14:00 Current Petitions Petitions · 11
  5. 14:00 Current Petitions Petitions · 3
  6. 14:00 Current Petitions Petitions · 3
  7. 14:00 Current Petitions Petitions · 39
  8. 14:00 Current Petitions Petitions · 3
  9. 14:00 Current Petitions Petitions · 17
  10. 14:00 Current Petitions Petitions · 3
  11. 14:00 Current Petitions Petitions · 3
  12. 14:00 Current Petitions Petitions · 13
  13. 14:00 Current Petitions Petitions · 6
  14. 14:00 Current Petitions Petitions · 5
  15. 14:00 Current Petitions Petitions · 4
  16. 14:00 Current Petitions Petitions · 4
  17. 14:00 Current Petitions Petitions · 16
  18. 14:00 Current Petitions Petitions · 4
  19. 14:00 Current Petitions Petitions · 4
  20. 14:00 Current Petitions Petitions · 8
  21. 14:00 Current Petitions Petitions · 5
  22. 14:00 Current Petitions Petitions · 15

The type of each item (debate, statement, questions, members’ business and so on) and the times shown are worked out by this site from headings, the chair’s opening words and the Official Report’s running timestamps. They are not the Parliament’s own classification. Text: the Scottish Parliament Official Report.